Clinical, genomic and immune microenvironmental determinants of nivolumab response in head and neck squamous cell carcinoma.

ABSTRACT:

Background

In view of improving biomarkers predicting the efficacy of immunotherapy for head and neck squamous cell carcinoma (R/M HNSCC), this multicenter retrospective study aimed to identify clinical, tumor microenvironmental, and genomic factors that are related to therapeutic response to the anti- Programmed cell death protein 1 (PD-1) antibody, nivolumab, in patients with R/M HNSCC.

Methods

The study compared 53 responders and 47 non-responders, analyzing formalin-fixed paraffin-embedded samples using 14-marker multiplex immunohistochemistry and targeted gene sequencing.

Results

Of 100 patients included, responders had significantly lower smoking and alcohol index, higher incidence of immune related adverse events, and higher PD-1 ligand (PD-L1) expression in im

SUBMITTER: Tsujikawa T 

PROVIDER: S-EPMC11317249 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature